Rankings
▼
Calendar
COLL Q1 2024 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena
COLL
Collegium Pharmaceutical, Inc.
$1B
Q1 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$145M
+0.1% YoY
Gross Profit
$91M
63.1% margin
Operating Income
$49M
34.1% margin
Net Income
$28M
19.1% margin
EPS (Diluted)
$0.71
QoQ Revenue Growth
-3.2%
Cash Flow
Operating Cash Flow
$62M
Free Cash Flow
$61M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$892M
Stockholders' Equity
$222M
Cash & Equivalents
$229M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$145M
$145M
+0.1%
Gross Profit
$91M
$77M
+18.2%
Operating Income
$49M
$25M
+100.9%
Net Income
$28M
-$17M
+259.0%
Revenue Segments
Belbuca
$51M
35%
Xtampza ER
$46M
32%
Nucynta IR
$26M
18%
Nucynta ER
$19M
13%
Symproic
$3M
2%
← FY 2024
All Quarters
Q2 2024 →